Key Segmentation
By Service Type
-
Contract Manufacturing
-
Contract Development
By Molecule Type
-
Small Molecules
-
Biologics
By End User
-
Big Pharma
-
Small and Mid-Sized Pharma and Biotech
-
Generic Pharma
By Development Phase
-
Preclinical
-
Phase I
-
Phase II
-
Phase III
-
Commercial
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Lonza, Samsung Biologics, WuXi Biologics, WuXi AppTec, FUJIFILM Diosynth Biotechnologies, Siegfried, Piramal Pharma Solutions, Divi's Laboratories, Sai Life Sciences, Pharmaron, Jubilant Pharmova, Curia, Recipharm, Syngene and Thermo Fisher Scientific (Patheon).
Key opportunities include biosimilar expansion, government manufacturing incentives, sterile fill-finish and advanced therapy capacity, and fast-growing Asia Pacific demand.
Growth of biologics and other complex drug pipelines, together with policies that diversify medicine supply chains, is the main growth factor.
By Service Type, the Contract Manufacturing segment dominated the market in 2025 with an estimated 59.19% share, supported by long-term commercial supply agreements.
North America dominated the market with a share of 34.00% in 2025, driven by the largest biotech sector and high drug launch activity.